Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Olschewski, H; Eber, E; Bucher, B; Hackner, K; Handzhiev, S; Hoetzenecker, K; Idzko, M; Klepetko, W; Kovacs, G; Lamprecht, B; Löffler-Ragg, J; Meilinger, M; Müller, A; Prior, C; Schindler, O; Täubl, H; Zacharasiewicz, A; Zwick, RH; Arns, BM; Bolitschek, J; Cima, K; Gingrich, E; Hochmair, M; Horak, F; Jaksch, P; Kropfmüller, R; Pfleger, A; Puchner, B; Puelacher, C; Rodriguez, P; Salzer, HJF; Schenk, P; Stelzmüller, I; Strenger, V; Urban, M; Wagner, M; Wimberger, F; Flick, H.
Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).
Wien Klin Wochenschr. 2022; 134(9-10):399-419
Doi: 10.1007/s00508-022-02018-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Olschewski Horst
- Co-Autor*innen der Med Uni Graz
- Eber Ernst
- Flick Holger
- Kovacs Gabor
- Meilinger Michael
- Pfleger Andreas
- Salzer Helmut J. F.
- Strenger Volker
- Wagner Marlies
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The Austrian Society of Pneumology (ASP) launched a first statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in May 2020, at a time when in Austria 285 people had died from this disease and vaccinations were not available. Lockdown and social distancing were the only available measures to prevent more infections and the breakdown of the health system. Meanwhile, in Austria over 13,000 patients have died in association with a SARS-CoV‑2 infection and coronavirus disease 2019 (COVID-19) was among the most common causes of death; however, SARS-CoV‑2 has been mutating all the time and currently, most patients have been affected by the delta variant where the vaccination is very effective but the omicron variant is rapidly rising and becoming predominant. Particularly in children and young adults, where the vaccination rate is low, the omicron variant is expected to spread very fast. This poses a particular threat to unvaccinated people who are at elevated risk of severe COVID-19 disease but also to people with an active vaccination. There are few publications that comprehensively addressed the special issues with SARS-CoV‑2 infection in patients with chronic lung diseases. These were the reasons for this updated statement. Pulmonologists care for many patients with an elevated risk of death in case of COVID-19 but also for patients that might be at an elevated risk of vaccination reactions or vaccination failure. In addition, lung function tests, bronchoscopy, respiratory physiotherapy and training therapy may put both patients and health professionals at an increased risk of infection. The working circles of the ASP have provided statements concerning these risks and how to avoid risks for the patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Austria - epidemiology
- COVID-19 - epidemiology
- Child - administration & dosage
- Communicable Disease Control - administration & dosage
- Humans - administration & dosage
- Lung Diseases - epidemiology, therapy
- Pulmonary Medicine - administration & dosage
- SARS-CoV-2 - administration & dosage
- Young Adult - administration & dosage
- Find related publications in this database (Keywords)
- Mechanical ventilation
- Immune modulators
- Chronic lung disease
- Pediatric lung disease
- Long covid